Overall, this editorial entitled HD-MTX and zanubrutinib combination therapy in PCNSL is well-written and contains useful information. The discussion of the topic was well done and well-founded. The bibliography is pertinent and current. Minor modifications have been suggested. I would suggest the authors include the following topic and references in the abstract:

Primary central nervous system lymphoma (PCNSL) is an unusual form of extranodal non-Hodgkin lymphoma that may affect the brain, leptomeninges, spinal cord or eyes, representing 3% of all intracranial neoplasms Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017:565-577.


I thank the reviewer for their suggestions.
I have cited the references suggested by the reviewer in the manuscript and highlighted them in yellow.